ARWR

Arrowhead Pharmaceuticals, Inc. exceeded expectations with ARO-MAPT phase 1 results, achieving up to 85% CSF tau reduction and validating its subcutaneous CNS siRNA platform. ARWR plans to expand its CNS pipeline, initiating two new ARO-MAPT phase 2 trials and advancing four additional CNS candidates into the clinic by end of 2027. Recent milestones include strong Redemplo phase 3 data, positive ARO-DIMER-PA results, and FDA STAR program entry for Redemplo, supporting a robust long-term growth outlook.

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from an ongoing Phase 1/2a study of ARO-MAPT, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for Alzheimer's disease and other tauopathies. These results represent the first successful clinical validation of a platform to deliver siRNA across the blood-brain barrier and achieve substantial target gene knockdown in the brain.

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted plozasiran entry in the Split Real Time Application Review (STAR) pilot program in connection with Arrowhead's upcoming supplemental new drug application (sNDA) for severe hypertriglyceridemia (sHTG). SHTG is a condition that significantly increases the risk of acute pancreatitis, which is associated with repeated hospital admiss.

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will focus on investigational therapy ARO-MAPT and Arrowhead's central nervous system (CNS) pipeline. The webinar will feature a presentation from Adam Boxer, M.D., Ph.D., Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF), where he directs.

Arrowhead Pharmaceuticals NASDAQ: ARWR is expanding its commercial and clinical footprint around RNA interference therapies, with its recently launched triglyceride-lowering treatment REDEMPLO and several pipeline programs targeting cardiometabolic disease, obesity and central nervous system disorders.

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

The transaction was valued at $1 million. The sale reduced the director's direct equity holdings by 9%.

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: 2026 Cantor Global Healthcare Conference – September 9-11, 2026 Type: Fireside Chat Presentation Date/Time: September 10, 2026, 10:55 am EDT Morgan Stanley 24th Annual Global Healthcare Conference – September 14-16, 2026 Type: Fireside Chat Presentation Date/Time: September 15, 2026, 11:30 am EDT H.C. Wainwright 28th Ann.